Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.
作者： Helga B. Salvesen , Ingunn Stefansson , May Britt Kalvenes , Soma Das , Lars A. Akslen
DOI: 10.1002/CNCR.10434
关键词:
摘要: BACKGROUND The PTEN tumor suppressor gene frequently is involved in endometrial carcinoma. Loss of heterozygosity and mutations reportedly are common, although the biologic importance these changes remain largely unknown. The objective this study was to assess pattern expression by immunohistochemistry a large series patients with carcinoma. METHODS A population-based 316 carcinoma who had long complete follow-up investigated for its correlation clinicopathologic variables, markers, survival. RESULTS PTEN protein mainly cytoplasmic cells, no seen 56 279 (20%) evaluable results. A heterogeneous staining found 70 tumors (25%). significant association between loss metastatic disease identified (P = 0.05). However, did not influence survival significantly. CONCLUSIONS The relatively frequent associated significantly disease. This indicates that system plays an important role some carcinomas, but further studies related various genetic alterations necessary. Cancer 2002;94:2185–91. © 2002 American Society. DOI 10.1002/cncr.10434
sci-hub.se 参考文章(25)
Marian S. Blazes, Kathleen R. Cho, Steven I. Wang, Ramon Parsons, Shikha Bose, Lora Hedrick Ellenson, Hironori Tashiro, Jing Li, Rong Wu, Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research. ,vol. 57, pp. 3935- 3940 ,(1997)
Andrew Berchuck, John I. Risinger, Patrice Watson, Henry T. Lynch, Jeff Boyd, Matthew F. Kohler, Genetic instability of microsatellites in endometrial carcinoma. Cancer Research. ,vol. 53, pp. 5100- 5103 ,(1993)
Andrew Berchuck, John I. Risinger, J. Carl Barrett, A. Kate Hayes, PTEN/MMAC1 Mutations in Endometrial Cancers Cancer Research. ,vol. 57, pp. 4736- 4738 ,(1997)
Motoko Unoki, Hiroyuki Kuramoto, Toyomi Satoh, Masato Nishida, Tatsuhiko Tsunoda, Toshihiro Tanaka, Mieko Matsushima-Nishiu, Yusuke Nakamura, Kenji Ono, Takeo Minaguchi, Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN Cancer Research. ,vol. 61, pp. 3741- 3749 ,(2001)
Helga B. Salvesen, Lars A. Akslen, Ole Erik Iversen, Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clinical Cancer Research. ,vol. 4, pp. 2779- 2785 ,(1998)
A Berchuck, J I Risinger, R K Dodge, J C Barrett, K Hayes, G L Maxwell, M E Carney, PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clinical Cancer Research. ,vol. 4, pp. 3005- 3010 ,(1998)
H. B. Salvesen, L. A. Akslen, T. Iversen, O. E. Iversen, Recurrence of endometrial carcinoma and the value of routine follow up British Journal of Obstetrics and Gynaecology. ,vol. 104, pp. 1302- 1307 ,(1997) , 10.1111/J.1471-0528.1997.TB10979.X
Aurel Perren, Liang-Ping Weng, Alexander H. Boag, Ulricke Ziebold, Kosha Thakore, Patricia L.M. Dahia, Paul Komminoth, Jacqueline A. Lees, Lois M. Mulligan, George L. Mutter, Charis Eng, Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast American Journal of Pathology. ,vol. 155, pp. 1253- 1260 ,(1999) , 10.1016/S0002-9440(10)65227-3
Ole E. Iversen, Flow cytometric deoxyribonucleic acid index: A prognostic factor in endometrial carcinoma American Journal of Obstetrics and Gynecology. ,vol. 155, pp. 770- 776 ,(1986) , 10.1016/S0002-9378(86)80018-7
Y. E. Whang, X. Wu, H. Suzuki, R. E. Reiter, C. Tran, R. L. Vessella, J. W. Said, W. B. Isaacs, C. L. Sawyers, Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 5246- 5250 ,(1998) , 10.1073/PNAS.95.9.5246